Search
Confirm
Cancel
News

News

Fusen Pharmaceutical Stock code:1652.HK
Location:
Homepage
-
-
The "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of Zhang Zhongjing pharmaceutical culture festival came to a successful conclusion!

The "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of Zhang Zhongjing pharmaceutical culture festival came to a successful conclusion!

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2021-11-01
  • Views:

(Summary description)On the 24th, the "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of this medical culture festival was held by the beautiful Danjiang lake. Leaders, experts, scholars and medical colleagues from all sides gathered together to give lectures, discuss Taoism, study scriptures, discuss the development plan of traditional Chinese medicine, and join hands to revitalize the health industry of traditional Chinese medicine.

The "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of Zhang Zhongjing pharmaceutical culture festival came to a successful conclusion!

(Summary description)On the 24th, the "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of this medical culture festival was held by the beautiful Danjiang lake. Leaders, experts, scholars and medical colleagues from all sides gathered together to give lectures, discuss Taoism, study scriptures, discuss the development plan of traditional Chinese medicine, and join hands to revitalize the health industry of traditional Chinese medicine.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2021-11-01 10:01
  • Views:
Information

▲   Shouzheng innovation - sub Forum on secondary development and large variety cultivation of traditional Chinese Medicine

On the morning of October 23, the 15th Zhang Zhongjing Medical Culture Festival and the 9th Zhongjing forum in Nanyang, China were grandly opened. The theme of this medical cultural festival is "inheriting the essence, guarding innovation, promoting the high quality development of Chinese medicine and industry", exploring the development of Chinese medicine and promoting the inheritance and innovation of traditional Chinese medicine culture. On the 24th, the "rightness and innovation - secondary development of traditional Chinese medicine and large variety cultivation forum" of Fusen pharmaceutical branch of this medical culture festival was held by the beautiful Danjiang lake. Leaders, experts, scholars and medical colleagues from all sides gathered together to give lectures, discuss Taoism, study scriptures, discuss the development plan of traditional Chinese medicine, and join hands to revitalize the health industry of traditional Chinese medicine.

I. speech by leaders

▲ speech by Zhang Changhe, deputy director of Nanyang traditional Chinese Medicine Development Bureau

At the meeting, Zhang Changhe, deputy director of the Nanyang Municipal Development Bureau of traditional Chinese medicine, pointed out that in May 12th this year, general secretary Xi Jinping visited Nanyang and made important instructions for the work of Chinese medicine, pointing out the way forward for the development of Chinese medicine. Nanyang is the hometown of Zhang Zhongjing, the medical saint. At present, Nanyang is working towards the grand goal of "global holy land of traditional Chinese medicine, national highland of traditional Chinese medicine and national famous capital of traditional Chinese medicine". As one of the leading enterprises of traditional Chinese medicine in Nanyang, Fusen pharmaceutical invited experts to deeply exchange the development opportunities of traditional Chinese medicine under the new situation and share the research results of secondary development and large variety cultivation of traditional Chinese medicine, which is not only of positive significance to the development of traditional Chinese medicine in Nanyang, but also bound to drive a large number of large varieties of traditional Chinese medicine to take off again and promote the rapid development of the traditional Chinese medicine industry.

▲   Mr. Cao Zhiming, President of Fusen pharmaceutical

Mr. Cao Zhiming, President of Fusen pharmaceutical, briefly introduced the enterprise profile and social contribution of Fusen pharmaceutical. President Cao has high hopes for the holding of this forum, and hopes that through this forum, everyone can further deepen their understanding and understanding of the development of traditional Chinese medicine, guide and promote the secondary development of traditional Chinese medicine with more scientific methods, and strengthen the positive and innovative development of traditional Chinese medicine industry, Make positive contributions to the leapfrog development of traditional Chinese medicine in the new historical period.

II. Expert report

▲   Deputy Secretary General Shen Nuo of China traditional Chinese Medicine Association made a report

Shen Nuo, Deputy Secretary General of China traditional Chinese Medicine Association, brought the report of "opportunities for traditional Chinese medicine industry under the new deal of traditional Chinese medicine". She elaborated the national strategic layout and policy support for traditional Chinese medicine industry under the new situation from four aspects: the new deal of traditional Chinese medicine, the development status and policy trend of traditional Chinese medicine industry, the strategic choice and strategic opportunities of traditional Chinese medicine industry, At the same time, it points out the development direction of traditional Chinese medicine industry in the future, and effectively improves everyone's confidence in the development of traditional Chinese medicine industry.

▲   Professor Wang Yi, Institute of pharmacoinformatics, Zhejiang University, made a report

Professor Wang Yi from the Institute of Pharmaceutical Informatics of Zhejiang University brought a special report on "Research on the secondary development and industrialization trend of Chinese patent medicine". Based on the background of the times and strategic needs, he expounded the core of the requirements for the inheritance, innovation and development of traditional Chinese medicine. Taking Tongmai oral liquid, Shuanghuanglian injection liquid and ganweikang tablets as examples, he creatively put forward the theory and strategy of the secondary development of large varieties of Chinese patent medicine, At the same time, based on the development of large health industry, imagine building a new traditional Chinese medicine industry system with industry as the core for upstream and downstream model innovation, and advocate the development of traditional Chinese medicine industry from extensive enterprises to quality-benefit enterprises.

Miao mingsan, vice president of Henan University of traditional Chinese medicine, made a special report on "secondary development and large variety cultivation of traditional Chinese medicine based on new use" at the meeting.

Dr. Gao Jin of the National Engineering and Technology Research Center for the modernization of traditional Chinese medicine brought a special report on "research and practice of secondary development and large variety cultivation of traditional Chinese medicine -- Taking Shenqi Fuzheng Injection and antiviral granules as examples".

Professor Fan Guanwei of Tianjin University of traditional Chinese medicine made a special report on "Research on pharmacodynamic material basis and action mechanism of Yuanhu Zhitong oral liquid".

Professor Xu Haiyu, Institute of traditional Chinese medicine, Chinese Academy of traditional Chinese medicine, made a special report on "integrated Pharmacology - Exploration and Research on Yuanhu Zhitong recipe".

Su Xiangfei, director of Standardization Office of Chinese society of traditional Chinese medicine, introduced at the meeting that "group standardization helps the high-quality development of traditional Chinese medicine industry".

III. unveiling ceremony

▲ Cao Zhiming, President of Fusen pharmaceutical, and Dr. Gao Jin of the national modern engineering technology center took a group photo for the unveiling

▲ group photo of the unveiling of the Branch Center for large varieties of traditional Chinese medicine and the Branch Center for research on the combination of medicine and nutrition

In order to further promote the secondary development and large variety cultivation of traditional Chinese medicine, the unveiling ceremony of the sub center of the National Engineering and Technology Research Center for the modernization of traditional Chinese medicine was held at the conference. Mr. Cao Zhiming, President of Fusen Pharmaceutical Co., Ltd. and Dr. Gao Jin of the National Engineering and Technology Research Center for the modernization of traditional Chinese medicine jointly unveiled the "National Engineering and Technology Research Center for the modernization of traditional Chinese medicine" and the "research sub center for the cultivation of large varieties of traditional Chinese Medicine" and the "research sub center for the combination of medicine and maintenance". The successful listing of the two sub centers marks a new step in the development of the modernization of traditional Chinese medicine of Fusen Pharmaceutical Co., Ltd.

▲ group photo of medical institutions and strategic partners of dealers

This forum is successfully concluded. In the future, forsen pharmaceutical company will unswervingly implement the development concept of "traditional Chinese medicine with the essence of inheritance and innovation", and make positive contributions to the development of China's traditional Chinese medicine.

Keyword:

Previous: None
Next: None
Previous: None
Next: None

Related News

Fusen

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
2022-04-26
Jiaheng

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
2022-04-19

WeChat

福森药业

Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by www.300.cn

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by www.300.cn